Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

S. Bertolini, N. Elicio, A. Daga, M. L. Degl'Innocenti, R. Balestreri, M. G. Fusi, A. M. Cotta Ramusino, A. Carozzi

Research output: Contribution to journalArticlepeer-review

Abstract

The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 1988

Keywords

  • fenofibrate
  • hyperlipoproteinaemia
  • pharmacokinetics
  • plasma lipids
  • single daily dose

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb'. Together they form a unique fingerprint.

Cite this